Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.

McClung, M R; Zanchetta, J R; Racewicz, A; Roux, C; Benhamou, C-L; Man, Z; Eusebio, R A; Beary, J F; Burgio, D E; Matzkin, E; Boonen, S; Delmas, P

McClung, M R; Zanchetta, J R; Racewicz, A; Roux, C; Benhamou, C-L; Man, Z; Eusebio, R A; Beary, J F; Burgio, D E; Matzkin, E; Boonen, S; Delmas, P.

Affiliation

McClung MR; Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USA. mmcclung@orost.com

Osteoporos Int ; 24(1): 293-9, 2013 Jan.

Article in En | MEDLINE | ID: mdl-22752050

Subject(s)

Bone Density Conservation Agents/administration & dosage; Etidronic Acid/analogs & derivatives; Osteoporosis, Postmenopausal/drug therapy; Administration, Oral; Aged; Biomarkers/blood; Bone Density/drug effects; Bone Density Conservation Agents/adverse effects; Bone Density Conservation Agents/therapeutic use; Double-Blind Method; Drug Administration Schedule; Etidronic Acid/administration & dosage; Etidronic Acid/adverse effects; Etidronic Acid/therapeutic use; Female; Femur/physiopathology; Humans; Lumbar Vertebrae/physiopathology; Middle Aged; Osteoporosis, Postmenopausal/physiopathology; Risedronic Acid; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteoporosis, Postmenopausal / Etidronic Acid / Bone Density Conservation Agents Type of study: Clinical_trials Limits: Aged / Female / Humans / Middle aged Language: En Journal: Osteoporos Int Journal subject: METABOLISMO / ORTOPEDIA Year: 2013 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google